{"entity":{"id":"ticaros","kind":"company","name":"TICAROS","aka":["TiCARos"],"tldr":"TICAROS is a Korean company making CAR-T cell therapy, in which a patient's own immune cells are engineered to recognise and kill cancer cells. Its first product, TC011, targets CD19 and is being tested in B-cell lymphomas that have come back or stopped responding.","summary":"TICAROS Co., Ltd., based in Seongdong-gu, Seoul, develops gene-modified T cell therapies. Its CLIP-CAR (Clamping-based Immunological Synapse Potentiating CAR) platform is designed to improve CAR-T efficacy, and it also lists a Converter CAR platform. TC011, an autologous anti-CD19 CAR-T, is in a multicentre phase 1/2 study in relapsed or refractory large B-cell non-Hodgkin lymphoma (NCT07473167, registered in March 2026 with a recorded start in August 2023) and a phase 2 study in relapsed or refractory follicular lymphoma (NCT07360288). The company reports receiving dual A ratings in the technology assessment for a KOSDAQ listing. Its first registered cancer trial, NCT07360288, was posted on ClinicalTrials.gov in January 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.ticaros.com/"},{"label":"ClinicalTrials.gov: phase 2 trial of TC011 in follicular lymphoma (NCT07360288)","url":"https://clinicaltrials.gov/study/NCT07360288"}],"tags":[],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07473167"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: ticaros.com English home page (address, platform names and a news headline about the KOSDAQ technology assessment). The site did not state TC011's target; CD19 comes from the ClinicalTrials.gov record NCT07473167.","Founding year not stated on the company website (only a 2020 copyright line). Listing status and financing were not confirmed; stage is a judgement.","The phase 1/2 record lists a start date in 2023 although it was posted in 2026; Korean-registry history was not checked."],"hq":"Seoul","country":"KR","companyType":"cell-therapy","website":"https://www.ticaros.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/ticaros/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"trial":[{"id":"nct07473167","kind":"trial","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","route":"/trials/nct07473167/"}]}}